Du-Ping Huang

Wenzhou Medical University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Fan Yang

First Affiliated Hospital of Wenzhou Medical University

Min Zheng

Wenzhou Medical University

Rongcheng Luo

Guangzhou University of Chinese Medicine

Zhiqiang Ye

First Affiliated Hospital of Wenzhou Medical University

Ruimin Ma

Chinese Academy of Sciences

Endong Chen

Wenzhou Medical University

Ying-Hao Wang

Mackay Memorial Hospital

Rutian Hao

First Affiliated Hospital of Wenzhou Medical University

Lizhi Lin

Wenzhou Medical University

Siyang Dong

First Affiliated Hospital of Wenzhou Medical University

Cooperative Institutions

Wenzhou Medical University

First Affiliated Hospital of Wenzhou Medical University

Sun Yat-sen University

Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University

Shanghai Jiao Tong University

Nanchang University

Shenzhen Institutes of Advanced Technology

Capital Medical University

Jacobson Holman (United States)

Central South University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women

Aging (2021)

Yinghao Wang Lizhi Lin Linhong Li Jialiang Wen Yili Chi

Considerable efforts have been devoted to exploring the breast cancer mutational landscape to understand its genetic complexity. However, no studies have yet comprehensively elucidated the molecular characterization of breast tumors in Chinese women. This study aimed to determine the potential clinical utility of peripheral blood assessment for circulating tumor-derived DNA (ctDNA) and comprehensively characterize the female Chinese population's genetic mutational spectrum. We used Omi-Seq to create cancer profiles of 273 patients enrolled at The First Affiliated Hospital of Wenzhou Medical University. The gene landscape results indicate PIK3CA and TP53 as the most frequently detected genes, followed by ERBB2, in Chinese breast cancer patients. The accuracy of ERBB2 copy number variations in tissue/formalin-fixed and paraffin-embedded samples was 95% with 86% sensitivity and 99% specificity. Moreover, mutation numbers varied between different molecular cell-free DNA subtypes, with the basal-like patients harboring a higher number of variants than the luminal patients. Furthermore, ratio changes in the max ctDNA allele fraction highly correlated with clinical response measurements, including cancer relapse and metastasis. Our data demonstrate that ctDNA characterization using the Omi-Seq platform can extend the capacity of personalized clinical cancer management.

10.18632/aging.202888

Cite

Citations (8)

The Influence of g.19124G>A Genetic Polymorphism in the OPG Gene on Bone Mineral Density in Chinese Women

Genetic Testing and Molecular Biomarkers (2013)

Jie Zhu Zitong Luo Yi Cao Menglei Yu J. Peng

The aim of this study was to detect the influence of g.19124G>A genetic polymorphism in the osteoprotegerin (OPG) gene on bone mineral density (BMD) and osteoporosis in Chinese postmenopausal women.A total of 403 primary osteoporosis subjects and 409 healthy controls were enrolled in this study. The BMD value of the femoral neck hip, lumbar spine (L(2-4)), and total hip was analyzed by Norland XR-46 dual energy X-ray absorptiometry. The polymerase chain reaction-restriction fragment length polymorphism method was utilized to investigate the genotype of g.19124G>A genetic polymorphism.We found significant differences of the femoral neck hip, lumbar spine (L(2-4)), and total hip of BMD among different genotypes of g.19124G>A genetic polymorphism, individuals with the genotype GG had significantly higher BMD than those of genotype GA and AA (p<0.05).These findings indicate that the g.19124G>A genetic polymorphism in the OPG gene is potentially related to BMD and osteoporosis in Chinese postmenopausal women, and the allele A could be associated with a lower BMD and an increased risk factor for osteoporosis.

Gene polymorphism

10.1089/gtmb.2013.0183

Cite

Citations (2)

MLF1IP promotes cells proliferation and apoptosis by regulating CyclinD1 in breast cancer.

PubMed (2017)

Fan Yang Ying-Hao Wang Siyang Dong Chengze Chen Du-Ping Huang

Breast cancer is the most frequently diagnosed cancer and the leading causes of cancer death among females in worldwide. It is urgent to develop novel biomarkers to improve risk stratification and optimize therapy choice. In our previous study, we firstly found that MLF1IP was upregulated in breast cancer tissue compared with adjacent normal tissue and patients with high MLF1IP expression had significantly lower overall survival. However, the biological function and cellular mechanisms of MLF1IP in breast cancer is still need to be elucidated. Here, we further investigated the role of MLF1IP in breast cancer by in vivo experiments. Our results showed that the expression level of MLF1IP was associated with lymph nodes metastasis and tumor size in clinical characteristic features. By biological function experiment, we found MLF1IP is correlated with cell proliferation and apoptosis and arrest cell cycle G1 through regulating Cyclin D1. Taken together, our findings suggested that MLF1IP could contribute to the oncogenic potential of breast cancer. To the best of our knowledge, it was firstly reported that MLF1IP was involved in breast cancer. This study provided a potential new marker and a target for gene therapy in breast cancer treatment.

Source

Cite

Citations (8)

Biochemical and Biophysical Research Communications (2016)

Xiao-He Ye Du-Ping Huang Rongcheng Luo

10.1016/j.bbrc.2016.11.051

Cite

Citations (28)

The Prognostic Value of the Expression of SMC4 mRNA in Breast Cancer

Disease Markers (2019)

Ruimin Ma Fan Yang Du-Ping Huang Min Zheng Yi-luan Wang

To investigate the mRNA expression and clinical significance of structural maintenance of chromosomes protein 4 (SMC4) in breast cancer.A total of 23 paired samples were sequenced, and data from the Cancer Genome Atlas were analyzed.SMC4 mRNA level was significantly upregulated in breast cancer tissues (P < 0.001). Patients with high mRNA expression of SMC4 had significantly poor survival (P = 0.012). Subgroup analyses show that in nontriple negative breast cancer (non-TNBC) patients, the high SMC4 mRNA expression, older age (>65), negative progesterone receptor, and advanced stages (III-IV) were independent risk factors (HR = 3.293, 95% CI 1.257-8.625, P = 0.015). In patients with TNBC, high mRNA expression of SMC4 correlated with better survival rate (P < 0.046).SMC4 mRNA level is a good prognostic biomarker for patients with breast cancer.

Clinical Significance

10.1155/2019/2183057

Cite

Citations (15)

Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer

Medical Oncology (2013)

Ruichao Zeng Wei Zhang Xing-qiang Yan Zhiqiang Ye Endong Chen

Plasma levels

Hematology

Triple-negative breast cancer

10.1007/s12032-013-0477-z

Cite